Conference Presentation Details - Overview
Merging and Redirecting Traffic: Exploiting the Biology of Renal Cell Carcinoma
Release Date: May 8, 2009|
Expiration Date: May 8, 2010
Apr 24, 2009, Chicago, IL
Lecture Overview
The Merging and Redirecting Traffic: Exploiting the Biology of Renal Cell Carcinoma symposium is designed to update physicians on the latest information regarding the optimal treatment of patients with renal cell carcinoma using targeted agents and how to integrate this information into everyday practice. The symposium focuses on the current standard of care for patients with newly diagnosed disease, the optimal sequence of targeted agents in individualized therapy, the potential role of combining therapeutics in maximizing patient benefit, and emerging therapeutic agents and how they will be integrated into the treatment algorithm. This symposium will also address current options for the treatment of advanced disease following progression on previous targeted agents.
This educational program is directed toward medical, surgical, and radiation oncologists with an interest in the treatment of kidney cancer. Fellows, oncology physician assistants, oncology nurses, and research nurses with an interest in the treatment of patients with kidney cancer are also invited to participate.
Upon completion of this educational activity, you should be able to:
- Evaluate the role of angiogenic and PI3K/Akt signaling pathways in the pathobiology of metastatic renal cell carcinoma and interpret efficacy and toxicity data from clinical trials
- Incorporate the use of approved targeted agents based on patient risk, treatment history, and evidence from clinical trials when formulating treatment decisions for advanced/metastatic renal cell carcinoma
- Discuss the optimal sequence of targeted agents in individualized therapy for refractory/recurrent disease
- Compare the utility of sequential monotherapy versus combination therapy with targeted agents in maximizing clinical benefit in patients with advanced renal cell carcinoma
Accreditation and Credit Designation
Physicians: Physicians’ Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians’ Education Resource designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA Category 1 CME credit for the PRA from organizations accredited by the ACCME.
Instructions for Participation
- Read the following information before entering the educational activity.
- Complete the Pretest.
- View the Flash video presentations and slides.
- Complete the Posttest.
- Answer the evaluation questions.
- After completion of the Pretest and successful completion of the Posttest and evaluation, you will receive your certificate online.
You will be permitted 2 attempts to successfully complete the Posttest.
You will be asked to login
or create an account.